Clinical trial
AZD1152 in Patients With Advanced Solid Malignancies
NCT00338182 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00338182 |
|---|---|
| Title | AZD1152 in Patients With Advanced Solid Malignancies |
| Official title | A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2-hour or 48-hour Intravenous Infusions in Patients With Advanced Solid Malignancies |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | AZD1152 part A, AZD1152 part B |
| Enrollment | 43 |
| Start date | May 23, 2006 |
| Primary completion | Jun 6, 2008 |
| Completion | Mar 1, 2017 |
| First posted | Jun 20, 2006 |
| Last update posted | Apr 24, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: